Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems

[1]  J. Zeng,et al.  Therapeutic management of metabolic dysfunction associated steatotic liver disease , 2024, United European gastroenterology journal.

[2]  M. Stepanova,et al.  Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. , 2024, Journal of hepatology.

[3]  Eric L. Johnson,et al.  Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67. , 2023, Diabetes care.

[4]  V. Wong,et al.  A multi-society Delphi consensus statement on new fatty liver disease nomenclature. , 2023, Annals of hepatology.

[5]  Shane P. Stenner,et al.  Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease , 2023, Hepatology communications.

[6]  B. Neuschwander‐Tetri,et al.  AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. , 2023, Hepatology.

[7]  R. Fox,et al.  Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey , 2022, Digestive Diseases and Sciences.

[8]  K. Cusi,et al.  American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). , 2022, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  C. Mantzoros,et al.  Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. , 2021, Gastroenterology.

[10]  S. McPhail,et al.  Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care , 2021, Internal medicine journal.

[11]  Sandra K Erickson.  Nonalcoholic fatty liver disease (NAFLD) , 2020, Definitions.

[12]  G. Kaplan,et al.  Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. , 2020, CMAJ open.

[13]  P. Angus,et al.  Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products , 2019, International journal of molecular sciences.

[14]  P. Tandon,et al.  Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care , 2019, Hepatology communications.

[15]  G. Su,et al.  Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both? , 2019, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

[16]  B. Cha,et al.  Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis , 2018, Diabetes & metabolism journal.